Interdigitating dendritic cell sarcoma: A rare malignancy responsive to ABVD chemotherapy

M. J. Olnes, T. Nicol, M. Duncan, Mark Bohlman, R. Erlich

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reticular cells. To date, there exists no consensus on a standard chemotherapeutic regimen for IDCS. Patients with this malignancy have been treated with chemotherapy regimens used against non-Hodgkin's lymphomas. Responses to these regimens have been variable, but mostly unsuccessful. In this article we describe a case of IDCS occurring in a 44 year old female who presented with abdominal pain and inguinal adenopathy. Staging of the tumor with CT scan, PET scan, and bone marrow biopsy demonstrated inguinal and abdominal lymphadenopathies, a large mass encasing the small bowel, and extensive liver infiltration. Morphologic and cytochemical analysis of biopsies from the abdominal mass and inguinal node were consistent with a diagnosis of IDCS, and immunohistochemical stains of the lymph node were positive for CLA, Kp-1, S-100, while negative for CD1a, CD3, CD20, CKER, and HMB-45. Treatment of this patient with ABVD chemotherapy resulted in rapid clinical improvement with a marked decrease in tumor burden after two cycles of ABVD, and a complete response after six cycles of therapy.

Original languageEnglish (US)
Pages (from-to)817-821
Number of pages5
JournalLeukemia and Lymphoma
Issue number4
StatePublished - 2002


  • ABVD
  • Chemotherapy
  • Interdigitating dendritic cell sarcoma
  • Malignancy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Interdigitating dendritic cell sarcoma: A rare malignancy responsive to ABVD chemotherapy'. Together they form a unique fingerprint.

Cite this